Search
Apronalide
go.drugbank.com/drugs/DB13221ApprovedApronalide is approved in Japan. Apronalide has been withdrawn from the market in many other countries due to patient development of thrombocytopenic purpura [A174814].
Bupranolol
go.drugbank.com/drugs/DB08808ExperimentalBupranolol is a non-selective beta blocker with potency similar to [propanolol]. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.
Anisodamine
go.drugbank.com/drugs/DB11785InvestigationalAnisodamine has been investigated for the treatment of Intestinal Diseases.
Categories: Compounds used in a research, industrial, or household settingStreptococcus pneumoniae type 22F capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB16710ApprovedInvestigationalIt is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection. … The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.
Nicotinamide riboside
go.drugbank.com/drugs/DB14933ApprovedInvestigationalWithdrawnNicotinamide riboside is under investigation in clinical trial NCT03432871 (Nicotinamide Riboside and Mitochondrial Biogenesis).
PX-12
go.drugbank.com/drugs/DB05448Investigationaltumor growth in animal models. … Since high levels of Trx-1 have been associated with colorectal, gastric and lung cancers, PX-12 is indicated as a potential cancer treatment in combination with chemotherapy for patients with advanced
Sagopilone
go.drugbank.com/drugs/DB12391InvestigationalIt is a so-called fully synthetic epothilone and is the first such compound to be in clinical development to combat several forms of cancer. … multidrug-resistant and paclitaxel-resistant tumor cell lines in vitro and in vivo.
Foslevodopa
go.drugbank.com/drugs/DB16683ApprovedFoslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants
MRK-003
go.drugbank.com/drugs/DB17015ExperimentalMRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682]
PEV3A
go.drugbank.com/drugs/DB05144InvestigationalPEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. It is a two-component vaccine that contains the virosome formulated peptide mimetics PEV301 and PEV302.